Individuals were classified as ‘AD' or ‘non-AD' on the basis of their CSF T-tau and amyloid Aβ1–42 profile measured using enzyme-linked immunosorbent assay; biomarkers of interest were compared using univariate and multivariate analyses. Here, MAPT is linked to Alzheimer disease.